MedTrace Logo

Impact of the Daily Doxycycline Pre-exposure Prophylaxis (PrEP) on the Incidence of Syphilis, Gonorrhoea and Chlamydia

NCT03709459 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2023-10-05

No results posted yet for this study

Summary

1\. This study is a non-randomized observational cohort trial using before and after comparison to evaluate intervention 2. It would mimic the conditions that would occur outside a clinical trial. 2. After consent and enrolment, all procedures will be guided by the Australian STI Management Guidelines.

3\. All enrolling participants will be offered daily doxycycline 100mg 4. All participants will be invited to complete a survey in every 3 months time for 12 months dated from participation.

5\. All follow-up information will be collected through electronic data capture to allow accurate and timely analyses.

6\. Data collection will be from (i) medical records (ii) online self-completed questionnaire

Conditions

  • STIs Prevention

Interventions

DRUG

Doxycycline

Participants will be asked to take Doxycycline 100mg/day for 12months duration

Sponsors & Collaborators

  • South Australian Health and Medical Research Institute

    collaborator OTHER

  • Monash University

    collaborator OTHER

  • Kirby Institute

    lead OTHER_GOV

Principal Investigators

  • Bridget Haire, PhD · Kirby Institute

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-17
Primary Completion
2024-07-17
Completion
2024-12-17

Countries

  • Australia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03709459 on ClinicalTrials.gov